These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 21983111)

  • 1. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial.
    Lamy A; Tong W; Gao P; Chrolavicius S; Gafni A; Yusuf S; Connolly SJ
    Can J Cardiol; 2012; 28(1):95-101. PubMed ID: 21983111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
    Connolly SJ; Eikelboom JW; Ng J; Hirsh J; Yusuf S; Pogue J; de Caterina R; Hohnloser S; Hart RG;
    Ann Intern Med; 2011 Nov; 155(9):579-86. PubMed ID: 22041946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
    Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
    J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
    N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
    Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
    J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
    Mahoney EM; Mehta S; Yuan Y; Jackson J; Chen R; Gabriel S; Lamy A; Culler S; Caro J; Yusuf S; Weintraub WS;
    Am Heart J; 2006 Jan; 151(1):219-27. PubMed ID: 16368322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    ; Connolly SJ; Pogue J; Hart RG; Hohnloser SH; Pfeffer M; Chrolavicius S; Yusuf S
    N Engl J Med; 2009 May; 360(20):2066-78. PubMed ID: 19336502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
    Lindgren P; Jönsson B; Yusuf S
    J Intern Med; 2004 May; 255(5):562-70. PubMed ID: 15078498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
    Hart RG; Bhatt DL; Hacke W; Fox KA; Hankey GJ; Berger PB; Hu T; Topol EJ;
    Cerebrovasc Dis; 2008; 25(4):344-7. PubMed ID: 18303254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention.
    Cowper PA; Udayakumar K; Sketch MH; Peterson ED
    J Am Coll Cardiol; 2005 Feb; 45(3):369-76. PubMed ID: 15680714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
    Hohnloser SH; Pajitnev D; Pogue J; Healey JS; Pfeffer MA; Yusuf S; Connolly SJ;
    J Am Coll Cardiol; 2007 Nov; 50(22):2156-61. PubMed ID: 18036454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
    Shah H; Gondek K
    Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction.
    Gibler KB; Huskamp HA; Sabatine MS; Murphy SA; Cohen DJ; Cannon CP
    Crit Pathw Cardiol; 2010 Mar; 9(1):14-8. PubMed ID: 20215905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.